Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Debiopharm Gets Global Rights To Repare
Generics BulletinMSN Laboratories’ proposed generic version of Novartis’ Entresto (sacubitril/valsartan) has been paused temporarily by the US Court of Appeals for the Federal Circuit, after the Indian firm inched clo
ScripTariffs, What Tariffs? Despite Liberation Day’s tariff announcements coming between the end of the first quarter and the announcement of first-quarter financials, most major pharmaceutical and generic